Postępowanie z hiperglikemią w cukrzycy typu 2: uzgodniony algorytm rozpoczynania i dostosowania terapii
Piśmiennictwo
1.
Sieradzki J. i wsp. Badanie PolDiab. Diabetol. Prakt. 2006:7:1
2.Sjöström
L., Narbro K., Sjöström D. at al. Effects of bariatric
surgery on mortality in swedish obese subjects. NEJM. 2007;357:741‑752
3. Davis B.J., Xie Z., Viollet B., Zou M.H.
Activation of the AMP-activated kinase by antidiabetic drug metformin
stimulates nitric oxide synthesis in vivo by promoting the association of heat
shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006;55:496‑505
4. UK Prospective Diabetes Study
(UKPDS). Group Effect of intensive blood glucose control with metformin on
complication in overweight patients with type 2 diabetes. Lancet.
1998;352:854‑865
5. Klimt CR., Knatternd GL., Meinert CL. The University Group Diabetes Program a study of the effect of
hypoglycemic agents on vascular complications in patients with adult-onset
diabetes 1. Design, methods and baseline characteristics. II. Mortality
results. Diabetes. 1970;Supl2:747‑830
6. Johnsen S.P., Rungby J. et al. Risk and
short-term prognosis of myocardial infarction among users of antidiabetic drug.
Am. J. Ther. 2006;13:134‑140
7. Chiasson J.L., Josse R.G., Gormis R., et al.
Acarbose treatment and the risk of cardiovascular disease and hypertension in
patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA
2003;290;486‑494
8. Dormandy J.A., Charbonnel B., Eckland D.J.A.
et al. Secondary prevention of macrovascular events in patients with type 2
diabetes in the PROactive: a randomized controlled trial. Lancet. 2005;366:1279‑1289
9. Nissen S.E., Wolski K. Effect of
rosiglitazone on the risk of myocardial infarction and death from cardiovascular
causes. NEJM. 2007;356:1‑10
10. Hollander P.A., Blonde L., Rowe R. et al. Efficacy and safety of inhaled insulin (Exubera) compared with
subcutaneous insulin therapy in patients with type 2 diabetes. Diabetes Care.
2004;27:256‑263
11. Holman R., Thorne
K., Farmer A. et al. Addition of biphasic, prandial, or basal insulin to oral
therapy in type 2 diabetes. NEJM.
2007;357:1‑15
